{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:18:34Z","timestamp":1791346714356,"version":"4.3.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.maturitas.2024.108159","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:43:58Z","timestamp":1732603438000},"page":"108159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy"],"prefix":"10.1016","volume":"193","author":[{"given":"Marla","family":"Shapiro C.M.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuegong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Morga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella E.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schaudig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2024.108159_bb0010","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women\u2019s health across the nation","volume":"96","author":"Gold","year":"2006","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.maturitas.2024.108159_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/13697130701744696","article-title":"Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States","volume":"11","author":"Williams","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2024.108159_bb0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/GME.0b013e31827d38a5","article-title":"Impact of the severity of vasomotor symptoms on health status, resource use, and productivity","volume":"20","author":"Whiteley","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2024.108159_bb0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/gme.0b013e318207851d","article-title":"A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women","volume":"18","author":"Blumel","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2024.108159_bb0030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/GME.0000000000000196","article-title":"Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study Cohort","volume":"21","author":"Freeman","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2024.108159_bb0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.maturitas.2024.108159_bb0040","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/jwh.2012.3719","article-title":"The impact of menopausal symptoms on quality of life, productivity, and economic outcomes","volume":"22","author":"Whiteley","year":"2013","journal-title":"J. Women's Health (Larchmt)"},{"key":"10.1016\/j.maturitas.2024.108159_bb0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/13697137.2012.688078","article-title":"Health-related quality of life of women with menopausal hot flushes and night sweats","volume":"16","author":"Ayers","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2024.108159_bb0050","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2024.108159_bb0055","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2024.108159_bb0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/GME.0000000000001793","article-title":"Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden","volume":"28","author":"Nappi","year":"2021","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2024.108159_bb0065","unstructured":"VEOZAH. Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216578s004lbl.pdf. (Accessed December 20 2024)."},{"key":"10.1016\/j.maturitas.2024.108159_bb0070","unstructured":"Veoza. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/veoza-epar-product-information_en.pdf. (Accessed March 25 2024)."},{"key":"10.1016\/j.maturitas.2024.108159_bb0075","unstructured":"Veoza. Swissmedic. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/marktueberwachung\/rmp\/fezolinetant_veoza_rmp-summary.pdf.download.pdf\/Fezolinetant_Veoza_Public_Risk_Management_Plan_Summary.pdf. (Accessed March 25 2024)."},{"key":"10.1016\/j.maturitas.2024.108159_bb0080","unstructured":"VEOZA. Therapeutic Goods Administration. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2024-PI-01388-1&d=20240314172310101. (Accessed March 25 2024)."},{"key":"10.1016\/j.maturitas.2024.108159_bb0085","unstructured":"Veoza. Public Assessment Report. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/452eebb63cf697a3a4bea8b85ed6effbfa0f7332. (Accessed May 14 2024)."},{"key":"10.1016\/j.maturitas.2024.108159_bb9000","unstructured":"Veoza. National Drug Information. Thai Food and Drug Administration. https:\/\/ndi.fda.moph.go.th\/uploads\/drug_detail_corporation\/doc\/word\/1263\/7da2f987ac81862a9307dca4e641557d-a1.pdf. (Accessed January 8 2025)."},{"key":"10.1016\/j.maturitas.2024.108159_bb0090","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","article-title":"Fezolinetant in the treatment of vasomotor symptoms associated with menopause","volume":"30","author":"Depypere","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.maturitas.2024.108159_bb0095","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2024.108159_bb0100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2024.108159_bb0105","article-title":"Efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms associated with menopause in individuals considered unsuitable for hormone therapy: the phase 3b randomized DAYLIGHT study","volume":"387","author":"Schaudig","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2024.108159_bb0110","unstructured":"PROMIS. https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis. (Accessed March 25 2024)."},{"key":"10.1016\/j.maturitas.2024.108159_bb0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.maturitas.2004.06.015","article-title":"Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire","volume":"50","author":"Lewis","year":"2005","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2024.108159_bb0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.maturitas.2024.108159_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00926230590475206","article-title":"The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores","volume":"31","author":"Wiegel","year":"2005","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.maturitas.2024.108159_bb0130","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.maturitas.2024.108159_bb0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2009.06.019","article-title":"A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population","volume":"122","author":"L\u00f6we","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.maturitas.2024.108159_bb0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.maturitas.2007.09.006","article-title":"Healthcare seeking and treatment for menopausal symptoms in the United States","volume":"58","author":"Williams","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2024.108159_bb0145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.maturitas.2007.02.021","article-title":"Quality of life (QOL) in menopause","volume":"57","author":"Utian","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2024.108159_bb0150","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s12325-024-02787-z","article-title":"Psychometric evaluation of the MENQOL instrument in women experiencing vasomotor symptoms associated with menopause","volume":"41","author":"Schultz","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.maturitas.2024.108159_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1477-7525-3-47","article-title":"Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review","volume":"3","author":"Utian","year":"2005","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.maturitas.2024.108159_bb0160","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/1471-0528.17773","article-title":"Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials","volume":"131","author":"Cano","year":"2024","journal-title":"BJOG"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512224002548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512224002548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T03:04:04Z","timestamp":1740366244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512224002548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"alternative-id":["S0378512224002548"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2024.108159","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2024.108159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108159"}}